

Rosetta Genomics sells PersonalizeDx, 11/17

November 2017—Rosetta Genomics entered into a definitive agreement in early September to sell all of its ownership interest in PersonalizeDx to Pragmin Prognosis. PDx is a molecular diagnostics and services company serving community-based pathologists, urologists, and oncologists with tests for various cancers including bladder, prostate, lung, breast, and hematological malignancies offered through a CLIA laboratory based in Lake Forest, Calif.

The purchase price is \$2.875 million in cash with \$1.25 million to be paid at closing.

[Rosetta Genomics](#), 877-429-6643